Game,

IMO IRB approval was most likely the final planning activity conducted by Cardiogenics in preparing to conduct the Beta-Site study; which means the Company has moved from planning to implementation. Hospital personnel who will perform the activities outlined in the clinical protocol have been or are now being trained/educated on the clinical protocol to ensure they perform the duties outlined.

Patient enrollment is an element of the clinical study over which Cardiogenics has very limited control, thus foolish for the Company to identify a specific date for completion of the trial. If the company has sufficient data on likely patient enrollment rates, Cardiogenics could make a qualifying statement that if enrollment continues as they have experienced or complies with predictive enrollment rates then the last patient is projected to be enrolled in the study within some number of weeks or some specific future month.

IMO Cardiogenics could issue a press release after the first patients are enrolled that announces the date of first enrollment. I hope Cardiogenics issues this announcement as IMO such announcement would help move the share price higher.

Ante